These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 10952476)
1. Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain. Moolenaar F; Meijler WJ; Frijlink HW; Visser J; Proost JH Eur J Clin Pharmacol; 2000 Jun; 56(3):219-23. PubMed ID: 10952476 [TBL] [Abstract][Full Text] [Related]
2. The influence of the route of administration: a comparative study at steady state of oral sustained release morphine and morphine sulfate suppositories. Du X; Skopp G; Aderjan R Ther Drug Monit; 1999 Apr; 21(2):208-14. PubMed ID: 10217341 [TBL] [Abstract][Full Text] [Related]
3. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain. Quigley C; Joel S; Patel N; Baksh A; Slevin M Palliat Med; 2003 Mar; 17(2):185-90. PubMed ID: 12701850 [TBL] [Abstract][Full Text] [Related]
4. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine. Kinzler ER; Pantaleon C; Iverson M; Aigner S Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis. Pauli-Magnus C; Hofmann U; Mikus G; Kuhlmann U; Mettang T Nephrol Dial Transplant; 1999 Apr; 14(4):903-9. PubMed ID: 10328468 [TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain. Babul N; Provencher L; Laberge F; Harsanyi Z; Moulin D J Clin Pharmacol; 1998 Jan; 38(1):74-81. PubMed ID: 9597563 [TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine. Stuart-Harris R; Joel SP; McDonald P; Currow D; Slevin ML Br J Clin Pharmacol; 2000 Mar; 49(3):207-14. PubMed ID: 10718775 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Thirlwell MP; Sloan PA; Maroun JA; Boos GJ; Besner JG; Stewart JH; Mount BM Cancer; 1989 Jun; 63(11 Suppl):2275-83. PubMed ID: 2720576 [TBL] [Abstract][Full Text] [Related]
12. Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects. Kinzler ER; Pantaleon C; Aigner S Clin Ther; 2018 Aug; 40(8):1357-1365. PubMed ID: 30049503 [TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain. De Gregori S; Minella CE; De Gregori M; Tinelli C; Ranzani GN; Govoni S; Allegri M; Regazzi M Ther Drug Monit; 2014 Jun; 36(3):335-44. PubMed ID: 24595069 [TBL] [Abstract][Full Text] [Related]
14. Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: a prospective survey in 300 adult cancer patients. Klepstad P; Dale O; Kaasa S; Zahlsen K; Aamo T; Fayers P; Borchgrevink PC Acta Anaesthesiol Scand; 2003 Jul; 47(6):725-31. PubMed ID: 12803591 [TBL] [Abstract][Full Text] [Related]
15. A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients. Oosten AW; Abrantes JA; Jönsson S; Matic M; van Schaik RHN; de Bruijn P; van der Rijt CCD; Mathijssen RHJ Clin Pharmacokinet; 2017 Jul; 56(7):733-746. PubMed ID: 27815868 [TBL] [Abstract][Full Text] [Related]
16. Steady-state kinetics and dynamics of morphine in cancer patients: is sedation related to the absorption rate of morphine? Christrup LL; Sjøgren P; Jensen NH; Banning AM; Elbaek K; Ersbøll AK J Pain Symptom Manage; 1999 Sep; 18(3):164-73. PubMed ID: 10517037 [TBL] [Abstract][Full Text] [Related]
17. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration. Wolff T; Samuelsson H; Hedner T Pain; 1995 Aug; 62(2):147-154. PubMed ID: 8545139 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients. Wilkinson TJ; Robinson BA; Begg EJ; Duffull SB; Ravenscroft PJ; Schneider JJ Cancer Chemother Pharmacol; 1992; 31(3):251-4. PubMed ID: 1464164 [TBL] [Abstract][Full Text] [Related]
19. The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide. Penson RT; Joel SP; Roberts M; Gloyne A; Beckwith S; Slevin ML Br J Clin Pharmacol; 2002 Apr; 53(4):347-54. PubMed ID: 11966664 [TBL] [Abstract][Full Text] [Related]
20. Steady-state pharmacokinetic evaluation of a novel, controlled-release morphine suppository and subcutaneous morphine in cancer pain. Bruera E; Fainsinger R; Spachynski K; Babul N; Harsanyi Z; Darke AC J Clin Pharmacol; 1995 Jul; 35(7):666-72. PubMed ID: 7560246 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]